La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Avinger Gestione

Gestione criteri di controllo 2/4

Avinger's Il CEO è Jeff Soinski, nominato in Dec2014, e ha un mandato di 9.67 anni. la retribuzione annua totale è $ 924.30K, composta da 43.3% di stipendio e 56.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.2% delle azioni della società, per un valore di $ 58.22K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 8.3 anni e 9.7 anni.

Informazioni chiave

Jeff Soinski

Amministratore delegato

US$924.3k

Compenso totale

Percentuale dello stipendio del CEO	43.3%
Mandato del CEO	9.8yrs
Proprietà del CEO	2.2%
Durata media del management	8.4yrs
Durata media del Consiglio di amministrazione	9.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jeff Soinski rispetto agli utili di Avinger?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$15m
Mar 31 2024	n/a	n/a	-US$16m
Dec 31 2023	US$924k	US$400k	-US$18m
Sep 30 2023	n/a	n/a	-US$19m
Jun 30 2023	n/a	n/a	-US$22m
Mar 31 2023	n/a	n/a	-US$22m
Dec 31 2022	US$605k	US$400k	-US$27m
Sep 30 2022	n/a	n/a	-US$28m
Jun 30 2022	n/a	n/a	-US$29m
Mar 31 2022	n/a	n/a	-US$27m
Dec 31 2021	US$595k	US$400k	-US$22m
Sep 30 2021	n/a	n/a	-US$21m
Jun 30 2021	n/a	n/a	-US$21m
Mar 31 2021	n/a	n/a	-US$22m
Dec 31 2020	US$505k	US$377k	-US$23m
Sep 30 2020	n/a	n/a	-US$23m
Jun 30 2020	n/a	n/a	-US$23m
Mar 31 2020	n/a	n/a	-US$24m
Dec 31 2019	US$607k	US$399k	-US$23m
Sep 30 2019	n/a	n/a	-US$24m
Jun 30 2019	n/a	n/a	-US$25m
Mar 31 2019	n/a	n/a	-US$26m
Dec 31 2018	US$1m	US$390k	-US$36m
Sep 30 2018	n/a	n/a	-US$39m
Jun 30 2018	n/a	n/a	-US$43m
Mar 31 2018	n/a	n/a	-US$49m
Dec 31 2017	US$522k	US$390k	-US$49m

Compensazione vs Mercato: La retribuzione totale di Jeff ($USD 924.30K ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 681.57K ).

Compensazione vs guadagni: La retribuzione di Jeff è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Jeff Soinski (62 yo)

9.8yrs

Mandato

US$924,295

Compensazione

Mr. Jeffrey M. Soinski, also known as Jeff, had been Independent Director at QSAM Biosciences, Inc. since March 02, 2022. Mr. Soinski has been Chief Executive Officer and Director of Avinger, Inc. since De...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jeffrey Soinski	CEO & Director	9.8yrs	US$924.30k	2.2% $ 49.8k
Nabeel Subainati	Vice President of Finance	2.2yrs	US$452.08k	0.20% $ 4.5k
Himanshu Patel	Chief Technology Officer	10.9yrs	US$614.58k	1.8% $ 40.6k
Keith Schaefer	Chief Operating Officer	no data	Nessun dato	Nessun dato
Philip Preuss	Chief Marketing Officer & VP of Business Operations	no data	Nessun dato	Nessun dato
Corey Gibbs	Vice President of Sales	7.1yrs	Nessun dato	Nessun dato
Jaafer Golzar	Chief Medical Officer	no data	Nessun dato	Nessun dato

8.4yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di AVGR è esperto e expertise (durata media dell'incarico 8.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jeffrey Soinski	CEO & Director	9.8yrs	US$924.30k	2.2% $ 49.8k
James McElwee	Independent Director	13.5yrs	US$140.00k	1.3% $ 29.4k
James Cullen	Independent Non-Executive Chairman & Lead Independent Director	9.8yrs	US$167.50k	1.3% $ 29.4k
Tamara Elias	Independent Director	4.8yrs	US$137.50k	1.3% $ 29.5k
Zhong Zhao	Director	less than a year	Nessun dato	Nessun dato

9.8yrs

Durata media

66.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AVGR sono considerati esperti (durata media dell'incarico 9.7 anni).

Avinger Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Avinger, Inc. Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer

Insufficient new directors

Avinger, Inc., Annual General Meeting, Dec 22, 2023

Insufficient new directors

Avinger, Inc. Appoints Nabeel Subainati as the Company’s Principal Financial Officer and Principal Accounting Officer, Effective Immediately

Avinger, Inc., Annual General Meeting, Oct 14, 2022

Recent updates

Avinger, Inc. Initiates Full Commercial Launch of Pantheris LV Image-Guided Atherectomy Device

Avinger, Inc. Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer

Avinger, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $5.996714 million.

Avinger, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.

Avinger, Inc. to Report Q1, 2024 Results on May 15, 2024

Avinger, Inc. to Report Q4, 2023 Results on Mar 20, 2024

Avinger, Inc. announced a financing transaction

Avinger's Securities Would Be Delisted At the Open of Business on November 30, 2023, Unless Company Timely Requests A Hearing Before the Nasdaq Hearings Panel

Insufficient new directors

Avinger's Securities Would Be Delisted At the Open of Business on November 30, 2023, Unless Company Timely Requests A Hearing Before the Nasdaq Hearings Panel

Avinger, Inc., Annual General Meeting, Dec 22, 2023

Consensus EPS estimates upgraded to US$3.59 loss, revenue downgraded

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Avinger, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Avinger, Inc. Initiates Full Commercial Launch of Tigereye St Image-Guided CTO Crossing Device

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Avinger, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Avinger, Inc. Receives 510(K) Clearance for Pantheris LV Image-Guided Atherectomy System

Avinger, Inc. Announces Successful First Cases with Tigereye ST Image-Guided Chronic Total Occlusion Crossing Device

Avinger Receives Non-Compliance Notice from Nasdaq Regarding Stockholders’ Equity Requirement

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings released: US$4.36 loss per share (vs US$4.57 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.77 loss per share (vs US$1.25 loss in 3Q 2021)

Avinger, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Avinger GAAP EPS of -$0.94 beats by $0.15, revenue of $2.13M misses by $0.25M

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $2.599923 million.

Avinger, Inc. announced that it expects to receive $2.400002 million in funding

Avinger, Inc. Appoints Nabeel Subainati as the Company’s Principal Financial Officer and Principal Accounting Officer, Effective Immediately

Avinger, Inc., Annual General Meeting, Oct 14, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$8.50

Consensus forecasts updated

Avinge Receives 510(K) Clearance from the U.S. Food & Drug Administration

Is Avinger (NASDAQ:AVGR) Using Debt Sensibly?

Third quarter 2021 earnings released: US$0.062 loss per share (vs US$0.079 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.037 loss per share (vs US$0.18 loss in 2Q 2020)

Is Avinger (NASDAQ:AVGR) A Risky Investment?

First quarter 2021 earnings released: US$0.067 loss per share (vs US$0.47 loss in 1Q 2020)

Avinger shares fall after Q1 results fail to impress Wall Street

Full year 2020 earnings released: US$0.47 loss per share (vs US$3.18 loss in FY 2019)

Avinger, Inc. to Report Q4, 2020 Results on Mar 11, 2021

Avinger Regains Compliance with Nasdaq Listing Requirements

Does Avinger (NASDAQ:AVGR) Have A Healthy Balance Sheet?

New 90-day high: US$0.89

Avinger 'Hot Penny Stock to buy' - Robinhood

New 90-day high: US$0.35

Avinger, Inc., Annual General Meeting, Dec 23, 2020

Avinger Receives Nasdaq Extension, Recommends Stockholders Vote for All Proxy Proposals

Third quarter 2020 earnings released: US$0.079 loss per share

Revenue beats expectations, earnings disappoint

Avinger, Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: US$0.29

New 90-day low: US$0.29

Analysts increase EPS estimates to -US$0.69

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $5.2 million.

New 90-day high - US$0.67

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $6 million.

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media